Contineum Therapeutics (CTNM) Current Assets (2023 - 2026)

Contineum Therapeutics' Current Assets history runs 4 years deep, the most recent figure standing at $253.0 million for Q1 2026.

• On a quarterly basis, Current Assets rose 31.66% year-over-year to $253.0 million in Q1 2026; TTM through Mar 2026 was $253.0 million, a 31.66% increase from a year earlier, with the FY2025 full-year figure at $267.9 million, up 29.81% from the prior year.
• Current Assets retreated to $253.0 million in Q1 2026 per CTNM's latest filing, from $267.9 million in the prior quarter.
• Across five years, Current Assets topped out at $267.9 million in Q4 2025 and bottomed at $119.7 million in Q1 2024.
• The 4-year median for Current Assets is $199.3 million (2024), against an average of $196.4 million.
• Across the five-year window, Current Assets soared 61.61% in 2024 and slipped 19.74% in 2025, its largest moves.
• Year by year, Current Assets stood at $127.7 million in 2023, then surged by 61.61% to $206.4 million in 2024, then gained by 29.81% to $267.9 million in 2025, then decreased by 5.58% to $253.0 million in 2026.
• Per Business Quant, the three latest CTNM Current Assets figures stand at $253.0 million (Q1 2026), $267.9 million (Q4 2025), and $184.9 million (Q3 2025).